![]() If disease progression or intervening therapy is evident, PSMA PET should be repeated. In terms of patient selection, workgroup members agreed that PSMA PET should be performed within three months of treatment or since progression on the last therapy to ensure that the current disease state is represented. ![]() The workgroup conducted a review of the four prospective phase 2 and phase 3 trials that used 177Lu-PSMA-617 registered on to develop consensus recommendations. To develop the patient selection criteria and determine appropriate use scenarios, SNMMI assembled an autonomous workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine in 177Lu-PSMA-617 radionuclide therapy. Food and Drug Administration approved 177Lu-PSMA-617 for the treatment of men with mCRPC after progressing on taxane-based chemotherapy and at least one line of androgen receptor pathway inhibitors (ARPI). The statement, published in the July issue of The Journal of Nuclear Medicine, also reviews current clinical struggles physicians face during treatment with 177Lu-PSMA-617 radionuclide therapy. Reston, VA-The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. ![]() Society of Nuclear Medicine and Molecular Imaging ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |